Blanket Purchase Agreement V797D40222-36C24924A0032

Abbott Molecular Inc., a subsidiary of Abbott Laboratories, holds a single-award Blanket Purchase Agreement valued at $2,037,738.45 with Veterans Integrated Service Network 9, funded by the Department of Veterans Affairs. Awarded on April 1, 2024, and extending through March 31, 2029, this indefinite delivery vehicle procures reagents and consumables for in vitro diagnostic equipment under the General Services Administration's In-Vitro Diagnostics, Reagents, Test (FSS-65-VII) schedule. The contract was established through a Special Notice published in October 2023 announcing the Department of Veterans Affairs' intent to award a sole-source agreement to Abbott Laboratories for supplies supporting the Alinity m molecular diagnostic analyzer at the Lexington Veterans Affairs Medical Center. Abbott Molecular was determined the sole eligible supplier due to its proprietary ownership of the Alinity m technology and diagnostic testing supplies. The contract is structured as a firm fixed-price agreement with no small business set-aside designation, reflecting Abbott's status as a large, established medical technology corporation. Performance takes place in Des Plaines, Illinois.

Three task orders have been issued against this blanket purchase agreement totaling approximately $2.4 million, with individual calls valued at $1,585,787.14 (base award, April 1, 2024), $343,039.29 (April 1, 2025), and $471,121.79 (April 1, 2026), all completing by March 31, 2029. These orders support Veterans Integrated Service Network 9's molecular diagnostic testing infrastructure, providing critical reagents and consumables for infectious disease screening, including COVID-19, human immunodeficiency virus, and hepatitis C testing, as well as supporting other clinical diagnostic applications. The procurement enables the VA to maintain consistent access to proprietary Alinity m testing supplies essential to veterans' healthcare delivery and diagnostic capabilities across the network.